Research programme: cancer therapeutics - Phylogica

Drug Profile

Research programme: cancer therapeutics - Phylogica

Latest Information Update: 30 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phoremost; Phylogica
  • Class
  • Mechanism of Action Transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 30 Apr 2015 Preclinical development is ongoing in Australia
  • 07 Apr 2015 PhoreMost in-licenses Phylomer® libraries from Phylogica
  • 20 Jul 2004 Preclinical trials in Breast cancer in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top